

Edgar Filing: Glickman Mark A - Form 3

	Date Exercisable	Expiration Date	(Instr. 4) Title	Amount or Number of Shares	Price of Derivative Security	Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	
Stock Option (right to buy)	Â (2)	04/09/2028	Common Stock	135,000	\$ 67.29	D	Â
Stock Option (right to buy)	Â (3)	11/28/2028	Common Stock	33,000	\$ 52.38	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Glickman Mark A C/O ESPERION THERAPEUTICS, INC. 3891 RANCHERO DRIVE, SUITE 150 ANN ARBOR, MI 48108	Â	Â	Â Chief Commercial Officer	Â

Signatures

/s/ Richard B. Bartram, by power of attorney 12/21/2018

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) These shares were acquired pursuant to a restricted stock unit award under the 2017 Inducement Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of Esperion Therapeutics, Inc. common stock. 25% of the restricted stock units vest on April 9, 2019 and the remainder shall vest in equal quarterly installments over a three (3) year period thereafter, subject to continued service.

(2) 25% of option vests on April 9, 2019 and the remainder shall vest in equal quarterly installments over a three (3) year period thereafter.

(3) 25% of option vests on November 28, 2019 and the remainder shall vest in equal quarterly installments over a three (3) year period thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.